Narcolepsy Type 1: A Breakthrough Treatment for Cognitive Function
A groundbreaking study has revealed a potential breakthrough in the treatment of cognitive symptoms in adults with Narcolepsy Type 1 (NT1). The research, published in JAMA Neurology, introduces Oveporexton, an oral orexin receptor 2 agonist, as a promising solution for improving attention, memory, and executive function.
The study, led by Gert Jan Lammers, MD, PhD, and his team, analyzed 112 participants in a phase 2 clinical trial. Participants were randomized to receive Oveporexton or a placebo, with doses ranging from 0.5/0.5 mg to 7 mg/placebo. The results were remarkable, showing significant improvements in cognitive measures over 8 weeks.
Key Findings:
- Oveporexton demonstrated moderate- to large-magnitude effects on cognitive functions, including attention, memory, and executive function.
- The Psychomotor Vigilance Task (PVT) revealed a 10-17% reduction in lapses for Oveporexton-treated participants.
- Continuous Paired Associate Learning (CPAL) test showed a 22-17% decrease in errors.
- Working memory, processing speed, and executive function also benefited from Oveporexton treatment.
This study builds upon previous research, which initially focused on Oveporexton's impact on microsleep rates in NT1 patients. The initial findings, presented at the 2025 SLEEP Annual Meeting, showcased a 60-70% reduction in microsleeps and a delay in their occurrence.
The implications of this study are significant, as they highlight the potential of Oveporexton as a comprehensive treatment for narcolepsy-related cognitive issues. The research team's conclusion emphasizes the need for further investigation into Oveporexton's effectiveness in improving daytime wakefulness and overall quality of life for adults with NT1.
Stay tuned for more updates on this exciting development in neurology treatment!
